Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder
Introduction. The prevalence of functional biliary disorders continues to increase with insufficient effectiveness of existing treatment approaches. Among them, functional biliary disorders of sphincter of Oddi account for at least 50%.Objective. To study efficacy, safety and tolerability of a fixed...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-05-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6175 |
| _version_ | 1797841680451239936 |
|---|---|
| author | S. N. Mekhtiev O. A. Mekhtieva Z. M. Ibragimova M. V. Ukhova A. V. Volnukhin |
| author_facet | S. N. Mekhtiev O. A. Mekhtieva Z. M. Ibragimova M. V. Ukhova A. V. Volnukhin |
| author_sort | S. N. Mekhtiev |
| collection | DOAJ |
| description | Introduction. The prevalence of functional biliary disorders continues to increase with insufficient effectiveness of existing treatment approaches. Among them, functional biliary disorders of sphincter of Oddi account for at least 50%.Objective. To study efficacy, safety and tolerability of a fixed combination of glycyrrhizic acid and ursodeoxycholic acid (Fosfogliv Urso) in capsule form in patients with functional biliary disorders of sphincter of Oddi.Materials and Methods. The study included 32 patients diagnosed with functional biliary sphincter of Oddi disorders established according to the Rome Criteria IV revision (2016). Patients received Fosfogliv Urso (250 mg ursodeoxycholic acid and 35 mg glycyrrhizic acid) 1 capsule 3 times a day for 8 weeks. Prior to treatment, all study participants underwent a standard set of laboratory and instrumental examinations.Results. Against the background of Fosfogliv Urso treatment, statistically significant decrease of biliary pain prevalence up to 48.3% (p < 0.001); intense biliary pain up to 11.4% (p < 0.0001); intensity of pain syndrome on visual analogue scale down to 1.7 ± 0.9 cm was registered (p < 0.0001). Alanine aminotransferase activity significantly decreased to 34.0 ± 4.0 U/L (p < 0.001). There was a tendency of choledochal diameter decrease to 0.57 ± 0.01 cm. Treatment efficacy was rated by patients as very good and good in 83.4% of cases. The safety profile was assessed as favorable and tolerability as satisfactory.Discussion. The results obtained were superior to those previously obtained for ursodeoxycholic acid monotherapy and confirmed the data of the previously conducted phase III study. The rationality of the combination is due to the mutual complementation and possible synergism of the pharmacological effects of glycyrrhizinic and ursodeoxycholic acids.Conclusion. The results obtained allow to recommend the prescription of Fosfogliv Urso in the complex scheme of treatment and prophylaxis of functional biliary disorders of sphincter of Oddi. |
| first_indexed | 2024-04-09T16:35:14Z |
| format | Article |
| id | doaj.art-3352edf7e1164e20874a009909f1ae5b |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:35:14Z |
| publishDate | 2021-05-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-3352edf7e1164e20874a009909f1ae5b2023-04-23T06:56:56ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-05-010510211010.21518/2079-701X-2021-5-102-1105604Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorderS. N. Mekhtiev0O. A. Mekhtieva1Z. M. Ibragimova2M. V. Ukhova3A. V. Volnukhin4Pavlov First Saint Petersburg State Medical University; Expert Gastroenterology CenterPavlov First Saint Petersburg State Medical University; Expert Gastroenterology CenterExpert Gastroenterology CenterExpert Gastroenterology CenterSechenov First Moscow State Medical University (Sechenov University)Introduction. The prevalence of functional biliary disorders continues to increase with insufficient effectiveness of existing treatment approaches. Among them, functional biliary disorders of sphincter of Oddi account for at least 50%.Objective. To study efficacy, safety and tolerability of a fixed combination of glycyrrhizic acid and ursodeoxycholic acid (Fosfogliv Urso) in capsule form in patients with functional biliary disorders of sphincter of Oddi.Materials and Methods. The study included 32 patients diagnosed with functional biliary sphincter of Oddi disorders established according to the Rome Criteria IV revision (2016). Patients received Fosfogliv Urso (250 mg ursodeoxycholic acid and 35 mg glycyrrhizic acid) 1 capsule 3 times a day for 8 weeks. Prior to treatment, all study participants underwent a standard set of laboratory and instrumental examinations.Results. Against the background of Fosfogliv Urso treatment, statistically significant decrease of biliary pain prevalence up to 48.3% (p < 0.001); intense biliary pain up to 11.4% (p < 0.0001); intensity of pain syndrome on visual analogue scale down to 1.7 ± 0.9 cm was registered (p < 0.0001). Alanine aminotransferase activity significantly decreased to 34.0 ± 4.0 U/L (p < 0.001). There was a tendency of choledochal diameter decrease to 0.57 ± 0.01 cm. Treatment efficacy was rated by patients as very good and good in 83.4% of cases. The safety profile was assessed as favorable and tolerability as satisfactory.Discussion. The results obtained were superior to those previously obtained for ursodeoxycholic acid monotherapy and confirmed the data of the previously conducted phase III study. The rationality of the combination is due to the mutual complementation and possible synergism of the pharmacological effects of glycyrrhizinic and ursodeoxycholic acids.Conclusion. The results obtained allow to recommend the prescription of Fosfogliv Urso in the complex scheme of treatment and prophylaxis of functional biliary disorders of sphincter of Oddi.https://www.med-sovet.pro/jour/article/view/6175ursodeoxycholic acidglycyrrhizic acidfunctional biliary disordersbiliary paincomplex therapy |
| spellingShingle | S. N. Mekhtiev O. A. Mekhtieva Z. M. Ibragimova M. V. Ukhova A. V. Volnukhin Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder Медицинский совет ursodeoxycholic acid glycyrrhizic acid functional biliary disorders biliary pain complex therapy |
| title | Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder |
| title_full | Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder |
| title_fullStr | Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder |
| title_full_unstemmed | Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder |
| title_short | Possibilities of combined therapy in patients with functional biliary sphincter of Oddi disorder |
| title_sort | possibilities of combined therapy in patients with functional biliary sphincter of oddi disorder |
| topic | ursodeoxycholic acid glycyrrhizic acid functional biliary disorders biliary pain complex therapy |
| url | https://www.med-sovet.pro/jour/article/view/6175 |
| work_keys_str_mv | AT snmekhtiev possibilitiesofcombinedtherapyinpatientswithfunctionalbiliarysphincterofoddidisorder AT oamekhtieva possibilitiesofcombinedtherapyinpatientswithfunctionalbiliarysphincterofoddidisorder AT zmibragimova possibilitiesofcombinedtherapyinpatientswithfunctionalbiliarysphincterofoddidisorder AT mvukhova possibilitiesofcombinedtherapyinpatientswithfunctionalbiliarysphincterofoddidisorder AT avvolnukhin possibilitiesofcombinedtherapyinpatientswithfunctionalbiliarysphincterofoddidisorder |